Metformin hydrochloride delayed release tablets – a comparative dissolution profiles study
DOI:
https://doi.org/10.30574/gscbps.2019.8.2.0119Keywords:
Metformin hydrochloride, Dissolution profiles, Multisource drugs, TabletsAbstract
Multisource or generic drugs represent an important decrease in treatment cost for multiple diseases, which improves patient’s medicine access. However, the therapeutic equivalence between original drugs (innovator) and generic or multisource drugs need to be demonstrated. Bioequivalence represents drug efficacy and higher security for patients, and it is considered as a fundamental factor for product commercialization. This work main objective was to make a comparison between the dissolution profiles of the original and multisource metformin hydrochloride tablets commercialized in Costa Rica. We used a validated analytical method to quantify metformin in dissolution medium, a phosphates buffered solution of pH (6.8 ± 0.05). The obtained results demonstrated products interchangeability using the model-independent similarity factor (f2) and difference factor (f1) criteria.
Metrics
References
Sibaja MA. (2014). Psychosocial characterization of medication consumption in Costa Rica. Reflections Magazine, 93 (2), 55–65.
Saavedra I, Iturriaga V, Ávila L and Quiñones L. (2011). Bio-exemption studies (in vitro) to establish equivalence of medications. Cuad Méd Social (Chile), 52 (2), 66–79.
OMS. (2002). Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products. World Health Organization.
CCSS. (2012). Medicines. Wellness Magazine, 43, 8 – 98.
Pereira-Vega Z. (2016). Supply and demand of therapeutic equivalence studies (in vitro and in vivo) of medicines in Costa Rica. Ongoing Technology, 29 (1), 18–27.
Segura L. (2017). Generic drugs: their economic importance in public health systems and the need for in vitro studies to establish their bioequivalence. Acting Thought, 108-120.
Jalali RK and Rasaily D. (n.d.). Generic Drug and Bioequivalence Studies. Pharmaceutical Medicine and Translational Clinical Research. Elsevier.
Samaniego J and Arias G. (2016). Qualification of the in vitro pharmaceutical equivalence by the HPLC methodology of four medications containing paracetamol, chlorphenamine maleate and phenylephrine hydrochloride tablets. Rev. Soc. Quim Peru., 82 (4).
FDA. (2015). Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Maryland: Center for Drug Evaluation and Research.
Marroum PJ. (2014). History and Evolution of the Dissolution Test. Dissolution Technologies, 11-16.
Tam Paiba C. (2013). Comparison of dissolution profiles of Amlodipine in 5 mg multifuente tablets and the innovative product. Trujillo, Peru.
Homšek I, Parojcic J, Dacevic M, Petrovic L and Jovanovic D. (2010). Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study. Arzneimittelforschung, 60(09), 553-559.
Zhou M, Xia L q and Wang, J. (2007). Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metabolism and Disposition, 1956-1962.
Cheng C, Yu L, Lee H, Yang C, Lue C and Chou C. (2004). Biowaiver extension potential to BCS Class III high solubility - low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences, 297 - 304.
Bailey C. (2017). Metformin: historical overview. Birmingham: Springer-Verlag Berlin Heidelberg.
Ministry of Health of Costa Rica. (s.f.). Validation Guide of Analytical Methods. Saint Joseph.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
